Teva Pharmaceutical Industries, Endo Pharmaceuticals, and Teikoku Pharma entered into settlements with California totaling nearly $70 million over inter-company agreements that kept more affordable drugs off the market, California Attorney General Xavier Becerra announced July 29.
The settlements address so-called “pay-for-delay” agreements—deals in which brand name drugmakers pay generic companies to keep a lower-cost product off the market, thus maintaining a monopoly and high prices after an original drug patent expires.
“These aren’t purchases people can skip for a month when they don’t fit into their budget, so we have to do what we can to make sure people have...
For more stories, analysis and expertiseOR Request Trial
(Updates story throughout.)